Preoperatively Predicting Human Epidermal Growth Factor Receptor 2-low Expression in Breast Cancer Using Neural Network Model Based on Multiparameter Magnetic Resonance Imaging

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2024 Dec 19

PMID 39698610

Authors

Suhong Zhao

Peipei Chen

Xiaojuan Wang

Zhaoxiu Zheng

Ruirui Hui

Guodong Pang

Affiliations

Soon will be listed here.

Abstract

Background: Preoperative prediction of human epidermal growth factor receptor 2 (HER2)-low expression using magnetic resonance imaging (MRI) can enhance the selection of clinical treatment strategies and enhance patient outcomes. Herein, we investigated the value of a neural network model constructed with multiparametric MRI in diagnosing HER2-low breast cancer.

Methods: This retrospective study involved two different centers. A total of 895 breast cancer patients (903 lesions) were enrolled from the Second Hospital of Shandong University (known as "Center 1") between January 2015 to December 2022. They were allocated to the training set (626 cases/632 lesions) and the internal validation set (269 cases/271 lesions). The external validation set included 100 patients (100 lesions) from the Qilu Hospital of Shandong University (referred to as "Center 2") between June 2021 to December 2022. All patients were subgrouped into HER2-low and HER2-0 expression groups. We used t-tests, Wilcoxon rank sum tests, and Chi-squared tests or Fisher's exact test to compare the dynamic contrast-enhanced MRI features (morphological/hemodynamic features), and the apparent diffusion coefficient (ADC) values. A neural network model was constructed using the Neuralnet package in R, with the architecture specified as c(5,2) for the hidden layers. Bootstrapping was used for internal validation. The diagnostic performance in the training set was analyzed using receiver operating characteristic (ROC) curves. The clinical effectiveness of the model was validated using a decision curve analysis (DCA).

Results: HER2-low breast cancer lesions had irregular morphology, high early enhancement rate, and low ADC value compared to HER2-0 expressed lesions. The differences were significant (P<0.05). We then constructed a neural network model using these significant variables. ROC analysis showed that the area under the ROC curve of the model for diagnosing HER2-low breast cancer in the training, internal validation, and external validation sets was 0.757 [95% confidence interval (CI): 0.712-0.802], 0.728 (95% CI: 0.658-0.798), and 0.791 (95% CI: 0.693-0.890), respectively. The DCA demonstrated that the net benefit of the model was significantly greater than zero at a predicted probability of 0.764.

Conclusions: The neural network model based on MRI features is an effective tool in predicting HER2-low breast cancer, which may facilitate clinical treatment decision-making.

References

Li Z, Ai T, Hu Y, Yan X, Nickel M, Xu X . Application of whole-lesion histogram analysis of pharmacokinetic parameters in dynamic contrast-enhanced MRI of breast lesions with the CAIPIRINHA-Dixon-TWIST-VIBE technique. J Magn Reson Imaging. 2017; 47(1):91-96. DOI: 10.1002/jmri.25762. View

Pinker K, Bickel H, Helbich T, Gruber S, Dubsky P, Pluschnig U . Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the "Breast Imaging Reporting and Data System" for multiparametric 3-T imaging of breast lesions. Eur Radiol. 2013; 23(7):1791-802. DOI: 10.1007/s00330-013-2771-8. View

Chen R, Qi Y, Huang Y, Liu W, Yang R, Zhao X . Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population. Breast Cancer Res Treat. 2022; 197(1):189-200. PMC: 9823013. DOI: 10.1007/s10549-022-06781-3. View

Cho N . Imaging features of breast cancer molecular subtypes: state of the art. J Pathol Transl Med. 2020; 55(1):16-25. PMC: 7829574. DOI: 10.4132/jptm.2020.09.03. View

Ab Mumin N, Ramli Hamid M, Wong J, Rahmat K, Ng K . Magnetic Resonance Imaging Phenotypes of Breast Cancer Molecular Subtypes: A Systematic Review. Acad Radiol. 2021; 29 Suppl 1:S89-S106. DOI: 10.1016/j.acra.2021.07.017. View

Molinelli C, Jacobs F, Marchio C, Pitto F, Cosso M, Spinaci S . HER2-Low Breast Cancer: Where Are We?. Breast Care (Basel). 2023; 17(6):533-545. PMC: 9801403. DOI: 10.1159/000527391. View

Chen T, Hsu Y, Chen C . Comparison of Neural Network and Logistic Regression Analysis to Predict the Probability of Urinary Tract Infection Caused by Cystoscopy. Biomed Res Int. 2022; 2022:5775447. PMC: 8960008. DOI: 10.1155/2022/5775447. View

Nave O, Elbaz M, Bunimovich-Mendrazitsky S . Analysis of a breast cancer mathematical model by a new method to find an optimal protocol for HER2-positive cancer. Biosystems. 2020; 197:104191. DOI: 10.1016/j.biosystems.2020.104191. View

Modi S, Park H, Murthy R, Iwata H, Tamura K, Tsurutani J . Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020; 38(17):1887-1896. PMC: 7280051. DOI: 10.1200/JCO.19.02318. View

10.

Marchio C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A . Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2020; 72:123-135. DOI: 10.1016/j.semcancer.2020.02.016. View

11.

Qian F, Mao Y, Dong J, Xie F, Fang X, Zhang Q . Development of a multiparametric model for predicting the response to neoadjuvant chemotherapy in breast cancer. Transl Cancer Res. 2024; 13(2):558-568. PMC: 10928635. DOI: 10.21037/tcr-23-770. View

12.

Van Poznak C, Somerfield M, Bast R, Cristofanilli M, Goetz M, Gonzalez-Angulo A . Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015; 33(24):2695-704. PMC: 5478102. DOI: 10.1200/JCO.2015.61.1459. View

13.

Portnow L, Kochkodan-Self J, Maduram A, Barrios M, Onken A, Hong X . Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics. 2023; 43(2):e220103. DOI: 10.1148/rg.220103. View

14.

Yang S, Lin J, Lu F, Han Z, Fu C, Lv P . Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. J Magn Reson Imaging. 2016; 45(1):270-280. DOI: 10.1002/jmri.25344. View

15.

Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J, Just M . Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8):1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. View

16.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

17.

Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L . Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022; 20(1):142. PMC: 9052533. DOI: 10.1186/s12916-022-02346-9. View

18.

Mutai R, Barkan T, Moore A, Sarfaty M, Shochat T, Yerushalmi R . Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast. 2021; 60:62-69. PMC: 8414540. DOI: 10.1016/j.breast.2021.08.016. View

19.

Burge C, Chang H, Apple S . Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?. Breast. 2005; 15(2):167-72. DOI: 10.1016/j.breast.2005.06.004. View

20.

Seyfettin A, Dede I, Hakverdi S, Duzel Asig B, Temiz M, Karazincir S . MR imaging properties of breast cancer molecular subtypes. Eur Rev Med Pharmacol Sci. 2022; 26(11):3840-3848. DOI: 10.26355/eurrev_202206_28951. View